Purchase and Sale Agreement (May 9th, 2017)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
April 28, 2017 John T. Curnutte, M.D., Ph.D. jcurnutte@portola.com Dear John, (May 8th, 2017)
This letter sets forth the amended terms and conditions of your employment with Portola Pharmaceuticals, Inc. (Portola or the Company), effective May 1, 2017.
January 25, 2017 John T. Curnutte, M.D., Ph.D. Dear John, (February 3rd, 2017)
This letter sets forth the terms and conditions of your part-time employment with Portola Pharmaceuticals, Inc. (Portola or the Company), effective February 1, 2017.
DELIVERED VIA EMAIL Tao Fu (August 5th, 2015)
On behalf of Portola Pharmaceuticals, Inc. ("Portola" or the "Company"), I am pleased to offer you an exempt position of Executive Vice President, Chief Commercial and Business Officer reporting directly to me. This role will be a member of the Portola executive committee.
FIRST AMENDMENT OF THE License and Collaboration AGREEMENT (May 13th, 2014)
This First Amendment of the License and Collaboration Agreement (this "First Amendment") is made and effective as of April 7, 2014 (the "First Amendment Effective Date") by and between Biogen Idec MA Inc., a corporation organized and existing under the laws of Massachusetts, having its principal place of business at 14 Cambridge Center, Cambridge, Massachusetts ("Biogen Idec") and Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA ("Portola"). Biogen Idec and Portola are referred to individually as a "Party" and collectively as the "Parties."
Second Amendment to Lease (March 19th, 2014)
This SECOND AMENDMENT TO LEASE (this "Amendment") is made and entered into as of the 14th day of March, 2014, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and PORTOLA PHARMACEUTICALS, INC., a Delaware corporation ("Tenant").
First Amendment to Lease (April 12th, 2013)
This FIRST AMENDMENT TO LEASE (First Amendment) is made and entered into as of the day of May, 2010, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (Landlord), and PORTOLA PHARMACEUTICALS, INC., a Delaware corporation (Tenant).
April 29, 2008 William Lis [Address] Dear Bill, (April 12th, 2013)
On behalf of Portola Pharmaceuticals, Inc. (Portola or the Company), I am pleased to offer you an exempt position of Vice President, Business & Commercial Operations, reporting to me.
January 6, 2011 John T. Curnutte, M.D., Ph.D. [Address] Dear John, (April 12th, 2013)
On behalf of Portola Pharmaceuticals, Inc. (Portola or the Company), I am pleased to offer you an exempt position of Executive Vice President, Research and Development, reporting to me.
License and Collaboration Agreement by and Between Portola Pharmaceuticals, Inc. And Biogen Idec MA Inc. (March 13th, 2013)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Second Amended and Restated License Agreement (March 13th, 2013)
This SECOND AMENDED AND RESTATED LICENSE AGREEMENT (the Agreement) is executed as of 20th day of December, 2010 (the Effective Date) by and between PORTOLA PHARMACEUTICALS, INC., having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA, 94080, United States (hereinafter referred to as Portola) and ASTELLAS PHARMA INC., having its principal place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (hereinafter referred to as Astellas). References to either party in this Agreement shall be deemed to include all Affiliates (hereinafter defined) of such party.
Clinical Collaboration Agreement (March 13th, 2013)
This CLINICAL COLLABORATION AGREEMENT (the Agreement) is entered into and made effective as of October 16, 2012 (the Effective Date), by and among Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA (Portola), Bristol-Myers Squibb Company, a corporation organized and existing under the laws of Delaware, having its principal place of business at 345 Park Avenue, New York, NY 10154 (BMS), and Pfizer Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 235 East 42nd Street, New York, New York 1017 (Pfizer). Each of Portola, BMS and Pfizer are referred to individually as a Party and collectively as the Parties.
January 6, 2011 John T. Curnutte, M.D., Ph.D. [Address] Dear John, (December 21st, 2012)
On behalf of Portola Pharmaceuticals, Inc. (Portola or the Company), I am pleased to offer you an exempt position of Executive Vice President, Research and Development, reporting to me.
April 29, 2008 William Lis [Address] Dear Bill, (December 21st, 2012)
On behalf of Portola Pharmaceuticals, Inc. (Portola or the Company), I am pleased to offer you an exempt position of Vice President, Business & Commercial Operations, reporting to me.
License and Collaboration Agreement by and Between Portola Pharmaceuticals, Inc. And Biogen Idec MA Inc. (December 21st, 2012)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Clinical Collaboration Agreement (December 21st, 2012)
This CLINICAL COLLABORATION AGREEMENT (the Agreement) is entered into and made effective as of October 16, 2012 (the Effective Date), by and among Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA (Portola), Bristol-Myers Squibb Company, a corporation organized and existing under the laws of Delaware, having its principal place of business at 345 Park Avenue, New York, NY 10154 (BMS), and Pfizer Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 235 East 42nd Street, New York, New York 1017 (Pfizer). Each of Portola, BMS and Pfizer are referred to individually as a Party and collectively as the Parties.
First Amendment to Lease (December 21st, 2012)
This FIRST AMENDMENT TO LEASE (First Amendment) is made and entered into as of the day of May, 2010, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (Landlord), and PORTOLA PHARMACEUTICALS, INC., a Delaware corporation (Tenant).
Second Amended and Restated License Agreement (December 21st, 2012)
This SECOND AMENDED AND RESTATED LICENSE AGREEMENT (the Agreement) is executed as of 20th day of December, 2010 (the Effective Date) by and between PORTOLA PHARMACEUTICALS, INC., having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA, 94080, United States (hereinafter referred to as Portola) and ASTELLAS PHARMA INC., having its principal place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (hereinafter referred to as Astellas). References to either party in this Agreement shall be deemed to include all Affiliates (hereinafter defined) of such party.
PORTOLA PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT November 18, 2011 (December 21st, 2012)
THIS THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the Agreement) is entered into as of the 18th day of November, 2011, by and among PORTOLA PHARMACEUTICALS, INC., a Delaware corporation (the Company), and the investors listed on Exhibit A hereto, referred to hereinafter as the Investors and each individually as an Investor.